COMMUNIQUÉS West-GlobeNewswire

AB Science obtient un brevet japonais pour l'utilisation du masitinib dans le traitement des formes progressives de la sclérose en plaques (SEP) jusqu'en 2041
21/01/2026
COMMUNIQUÉ DE PRESSE AB SCIENCE OBTIENT UN BREVET JAPONAIS POUR L'UTILISATION DU MASITINIB DANS LE TRAITEMENT DES FORMES PROGRESSIVES DE LA SCLÉROSE EN PLAQUES (SEP) JUSQU'EN 2041 IL S'AGIT DU PREMIER PAYS À OCTROYER LE [...]
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101)
21/01/2026
OSE Immunotherapeutics Welcomes FDA Orphan Drug Designation Granted to Pegrizeprument (VEL-101) Nantes, France, January 21, 2026 – 6pm CET - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE), today acknowledges [...]
OSE Immunotherapeutics salue l'octroi de la désignation de médicament orphelin par la FDA du pegrizprument (VEL-101)
21/01/2026
OSE Immunotherapeutics salue l'octroi de la désignation de médicament orphelin par la FDA du pegrizprument (VEL-101) Nantes, le 21 janvier, 18 heures - OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnémo : OSE) prend [...]
IBA – TRANSPARENCY NOTIFICATION
21/01/2026
(Article 14, paragraph 1 of the law of 2 May 2007 on the disclosure of major holdings) Louvain-la-Neuve, Belgium, January 21, 2026 06:00 PM Summary of the notification IBA (Ion Beam Applications), the world leader in [...]
IBA SA – NOTIFICATION TRANSPARENCE
21/01/2026
(article 14, alinéa 1er de la loi du 2 mai 2007 relative à la publicité des participations importantes) Louvain-la-Neuve, Belgique, le 21 janvier 2026, 18:00 Résumé de la notification IBA (Ion Beam Applications SA), le [...]
Nation’s Top 40 High School Scientists to Compete for $1.8 Million in Awards at the Prestigious Regeneron Science Talent Search
21/01/2026
The Regeneron Science Talent Search Honors America’s Brightest Young Scientists Advancing Discovery and Innovation TARRYTOWN N.Y. and WASHINGTON, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Society for Science (the Society) and [...]
Arbitration tribunal upholds Ipsen’s termination of R&D agreement with Galderma
21/01/2026
PARIS, FRANCE, 21 January 2026 – Ipsen (Euronext: IPN; ADR: IPSEY) announced that the Arbitral Tribunal of the International Chamber of Commerce (ICC) has issued a final decision in favor of Ipsen, dismissing the claim [...]
Le tribunal arbitral confirme la résiliation par Ipsen de l'accord de R&D conclu avec Galderma
21/01/2026
PARIS, FRANCE, 21 janvier 2026 - Ipsen (Euronext : IPN ; ADR : IPSEY) annonce que le Tribunal arbitral de la Chambre de commerce internationale (CCI) a rendu une décision finale en faveur d'Ipsen, rejetant la demande [...]
HNL Lab Medicine Expands Services with New Pocono Creek Patient Service Center Featuring Dedicated Pediatric Phlebotomy Space
21/01/2026
BARTONSVILLE, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- HNL Lab Medicine, a trusted leader in comprehensive laboratory testing services, is pleased to announce the opening of its newest Patient Service Center in [...]
FSR Announces $400,000 Investment in New Round of Cardiac and Pilot Grant Awards to Drive Breakthroughs in Diagnosis and Treatment of Sarcoidosis
21/01/2026
CHICAGO, Jan. 21, 2026 (GLOBE NEWSWIRE) -- The Foundation for Sarcoidosis Research (FSR) has awarded four grants in the amount of $100,000 each to Dr. Christen Vagts from the University of Illinois at Chicago, Dr. Chieh [...]
Alignment Healthcare Named to the 2026 Fortune World’s Most Admired Companies™ List for First Time
21/01/2026
In its first year of eligibility, award-winning Medicare Advantage company earns spot on global corporate reputation list, joining major corporations like Amazon and Apple ORANGE, Calif., Jan. 21, 2026 (GLOBE NEWSWIRE [...]
CS Group (OTCQB: CSDX) Announces Multi-Channel Sales Model, Global Logistics Partners, and Sustainable Innovation Roadmap for MEDUSA SDP
21/01/2026
CHEYENNE, Wyo., Jan. 21, 2026 (GLOBE NEWSWIRE) -- CS Diagnostics Corp. (OTCQB: CSDX) today detailed its multi-channel sales strategy , global logistics partnerships , and sustainability roadmap supporting the commercial [...]
“Medical Travel Month” January 2026 Sponsored by Medical Travel & Digital Health News in SHSMD American Hospital Association’s Calendar of Health Observances
21/01/2026
OAKLAND, N.J., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Medical Travel & Digital Health News (MTDHN) , the leading bi-monthly online newsletter covering the business of medical travel and digital solutions worldwide, today [...]
Manhattan Wellness Joins Lumina Therapy Alliance, Expanding the Nation’s Premier In-Person Mental Health Network
21/01/2026
Led by visionary founder Jennifer Teplin, Manhattan Wellness strengthens Lumina’s footprint for New York’s business community and signals rapid national expansion. NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- Lumina [...]
PerfectServe is Furthest in Vision and Highest in Execution in 2026 Gartner® Magic Quadrant™ for Clinical Communication and Collaboration
21/01/2026
Marks the company’s third consecutive placement as a Leader following recognition as highest in execution in 2023 and furthest in vision in 2024 KNOXVILLE, Tenn., Jan. 21, 2026 (GLOBE NEWSWIRE) -- PerfectServe ® , a [...]
Human Continuum Appoints Dr. Tsun “Sean” Law MD, MBA as its Chief Executive Officer to Lead the Research and Development Efforts Focused on Next-Generation Exosome Therapies and Over-the-Counter Exosome-based Products
21/01/2026
New York, N.Y., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Human Continuum Inc. (“HC” or “the Company”) , a developer of platelet-derived and plant-based exosome therapeutics and diagnostics, today announced that it has [...]
LiveWorld Announces Human-Led, AI-Powered Strategy & 2026 Solutions Roadmap
21/01/2026
Company Unveils Seven AI Solutions for 2026, Built for The New Era of Healthcare Marketing CAMPBELL, Calif. and NEW YORK, Jan. 21, 2026 (GLOBE NEWSWIRE) -- LiveWorld, Inc. (OTC Markets: LVWD). For nearly three decades, [...]
Actuate Therapeutics Announces Plans to Expand Clinical Pipeline, Advancing Elraglusib Tablet into a Phase 1/2 Clinical Program in Refractory Cancers
21/01/2026
-Initiation of phase 1 portion of the trial planned in 2H 2026 -Phase 2 portion of the trial will initiate development of the elraglusib tablet in specific indications, including refractory melanoma and additional [...]
Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
21/01/2026
MALVERN, Pa., Jan. 21, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. (Nasdaq: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, today announced the pricing of its underwritten offering of 15,000 [...]

Pages